<DOC>
	<DOCNO>NCT01947309</DOCNO>
	<brief_summary>The primary objective study document efficacy safety data real-world set Chinese multiple myeloma patient receive least one prior therapy treat REVLIMID ( lenalidomide ) .</brief_summary>
	<brief_title>Observational Registry Study Chinese Patients Treated With Revlimid ( Lenalidomide )</brief_title>
	<detailed_description>This registry prospective , multi-center , observational study collect efficacy safety data multiple myeloma adult patient receive least one prior therapy take REVLIMID part standard care associate patient ' treatment order characterize use , efficacy outcome REVLIMID treatment . The registry capture data 600 patient prescribe REVLIMID specified hospital patient follow registry two year enrollment last patient .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must understand voluntarily sign write informed consent At least 18 year old time signing informed consent Diagnosed Multiple Myeloma Must receive least one prior Multiple Myeloma treatment time sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Revlimid , lenalidomide , multiple myeloma , PFS , Response Rates</keyword>
</DOC>